RPGR-associated retinopathy: clinical features, molecular genetics, animal models and therapeutic options. Issue 8 (3rd February 2016)

• Record Type: Journal Article
• Authors: Tee, James J L; Smith, Alexander J; Hardcastle, Alison J; Michaelides, Michel
• Is Part Of: British journal of ophthalmology. Volume 100:Issue 8(2016)
• Page Start: 1022
• Page End: 1027
• Publication Date: 2016-02-03
• Subjects: Retina -- Genetics -- Dystrophy; Ophthalmology -- Periodicals; 617.7
• DOI: 10.1136/bjophthalmol-2015-307698
• Languages: English
• ISSNs: 0007-1161

Abstract

Abstract : Retinitis pigmentosa GTPase regulator (RPGR) gene sequence variants account for the vast majority of X linked retinitis pigmentosa (RP), which is one of the most severe forms of RP. Symptoms of nyctalopia typically begin in childhood, with increasing loss of peripheral visual field during teenage years, and progressive central visual loss during the second to fourth decade of life. There is however marked intrafamilial and interfamilial phenotypic heterogeneity in affected males and carrier females. There is now a far greater understanding of the range of phenotypes associated with variants in this gene; including rod-cone dystrophy, cone-rod dystrophy, cone dystrophy, macular dystrophy and non-ocular phenotypes. There are also increasingly established genotype-phenotype associations and structure-function correlations. RPGR is involved in ciliary function, with ciliary dysfunction now recognised as the mechanism underlying a large proportion of inherited retinal disease. There has been significant progress in identifying naturally occurring animal models and developing novel models to define the underlying disease mechanisms and to test gene replacement therapy, in addition to advances in human retinal imaging, culminating in completed and planned clinical trials. These significant developments will be discussed.